» Articles » PMID: 38779685

Efferocytosis by Macrophages in Physiological and Pathological Conditions: Regulatory Pathways and Molecular Mechanisms

Overview
Journal Front Immunol
Date 2024 May 23
PMID 38779685
Authors
Affiliations
Soon will be listed here.
Abstract

Efferocytosis is defined as the highly effective phagocytic removal of apoptotic cells (ACs) by professional or non-professional phagocytes. Tissue-resident professional phagocytes ("efferocytes"), such as macrophages, have high phagocytic capacity and are crucial to resolve inflammation and aid in homeostasis. Recently, numerous exciting discoveries have revealed divergent (and even diametrically opposite) findings regarding metabolic immune reprogramming associated with efferocytosis by macrophages. In this review, we highlight the key metabolites involved in the three phases of efferocytosis and immune reprogramming of macrophages under physiological and pathological conditions. The next decade is expected to yield further breakthroughs in the regulatory pathways and molecular mechanisms connecting immunological outcomes to metabolic cues as well as avenues for "personalized" therapeutic intervention.

Citing Articles

The efferocytosis dilemma: how neutrophil extracellular traps and PI3K/Rac1 complicate diabetic wound healing.

Xie Y, Yang J, Zhu H, Yang R, Fan Y Cell Commun Signal. 2025; 23(1):103.

PMID: 39985056 PMC: 11844175. DOI: 10.1186/s12964-025-02092-4.


Screening and regulatory mechanism exploration of M1 macrophage polarization and efferocytosis-related biomarkers in coronary heart disease.

Gao H, Li J, Huang J, Jiang X Front Cardiovasc Med. 2024; 11:1478827.

PMID: 39723414 PMC: 11669322. DOI: 10.3389/fcvm.2024.1478827.

References
1.
Barreda D, Grinstein S, Freeman S . Target lysis by cholesterol extraction is a rate limiting step in the resolution of phagolysosomes. Eur J Cell Biol. 2024; 103(1):151382. DOI: 10.1016/j.ejcb.2023.151382. View

2.
Schilperoort M, Ngai D, Katerelos M, Power D, Tabas I . PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages. Nat Metab. 2023; 5(3):431-444. PMC: 10050103. DOI: 10.1038/s42255-023-00736-8. View

3.
Patten D . SCARF1: a multifaceted, yet largely understudied, scavenger receptor. Inflamm Res. 2018; 67(8):627-632. PMC: 6028831. DOI: 10.1007/s00011-018-1154-7. View

4.
Karunakaran U, Elumalai S, Moon J, Won K . CD36 Signal Transduction in Metabolic Diseases: Novel Insights and Therapeutic Targeting. Cells. 2021; 10(7). PMC: 8305429. DOI: 10.3390/cells10071833. View

5.
Jeon J, Buelow D, Garrison D, Niu M, Eisenmann E, Huang K . TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI Insight. 2020; 5(23). PMC: 7714403. DOI: 10.1172/jci.insight.140169. View